Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
BMC Res Notes ; 12(1): 496, 2019 Aug 09.
Article in English | MEDLINE | ID: mdl-31399137

ABSTRACT

OBJECTIVE: We recently reported that curcumin supplementation in a metabolically (i.e., Western diet [WD]) and chemically (i.e., CCl4) induced female rat model of non-alcoholic steatohepatitis (NASH) was associated with lower liver pathology scores and molecular markers of inflammation. This occurred when curcumin was given during induction of disease (preventative arm; 8-week WD with or without curcumin [8WD + C vs. 8WD]) as well as when given after disease development (treatment arm; 12-week WD with or without curcumin during weeks 9-12 [12WD + C vs. 12WD]). Herein, we sought to extend our findings from that study by determining the effects of curcumin supplementation on cytokine/chemokine expression in serum collected from these same rats. RESULTS: 24 cytokines/chemokines were assayed. IL-2 (+ 80%) and IL-13 (+ 83%) were greater with curcumin supplementation in the prevention arm. IL-2 (+ 192%), IL-13 (+ 87%), IL-17A (+ 81%) and fractalkine (+ 121%) were higher while RANTES was lower (- 22%) with curcumin supplementation in the treatment arm (p < 0.05 for all). RANTES concentrations also correlated significantly with hepatic pathology scores of inflammation (r = 0.417, p = 0.008). Select serum cytokines/chemokines were affected with curcumin supplementation in this female rat model of NASH. Moreover, curcumin's effect(s) on RANTES and its association with liver disease pathogenesis and progression may warrant further investigation.


Subject(s)
Anti-Inflammatory Agents/pharmacology , Curcumin/pharmacology , Dietary Supplements , Gene Expression Regulation/drug effects , Liver/drug effects , Non-alcoholic Fatty Liver Disease/diet therapy , Animals , Carbon Tetrachloride/administration & dosage , Chemokine CCL5/blood , Chemokine CCL5/genetics , Chemokine CX3CL1/blood , Chemokine CX3CL1/genetics , Diet, Western/adverse effects , Disease Models, Animal , Drug Administration Schedule , Female , Humans , Interleukin-13/blood , Interleukin-13/genetics , Interleukin-17/blood , Interleukin-17/genetics , Interleukin-2/blood , Interleukin-2/genetics , Liver/metabolism , Liver/pathology , Non-alcoholic Fatty Liver Disease/blood , Non-alcoholic Fatty Liver Disease/etiology , Non-alcoholic Fatty Liver Disease/genetics , Rats , Rats, Wistar , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...